Washington, DC, USA and Richmond, British Columbia, Canada – September 4, 2012 – Bioscan, Inc., a leading supplier of preclinical molecular imaging technologies, and Sonix Medical Corporation, a leading developer and manufacturer of high quality diagnostic ultrasound imaging systems, have entered into a Supply Agreement. Under the Agreement, Sonix will supply specialized ultrasound imaging products to Bioscan for use in the preclinical imaging market. The launch of the preclinical ultrasound systems, to be marketed under the BioSONIC WAVE™ and BioSONIC VIEW™ brand names, brings the next generation of high-frequency ultrasound imaging technologies to life sciences researchers.
“Bioscan is thrilled to establish this partnership with Sonix,” commented Staf van Cauter, President and CEO of Bioscan. “By introducing the BioSONIC line of preclinical ultrasound imagers to our customers, Bioscan becomes the first and only company in the preclinical imaging market to offer innovative solutions in all major in-vivo imaging modalities.”
The BioSONIC product line offers researchers access to advanced high-resolution ultrasound imaging capabilities in a user-friendly package appropriate to today’s challenging funding environment. Key features include:
· Customizable, intuitive touch-screen interface
· Imaging of mice and larger animal models with a single, portable system
· Easy co-registration of 3D ultrasound with other Bioscan imaging modalities
· Free-hand 3D/4D imaging for real-time accurate quantification
· Limitless field-of-view through exclusive panoramic imaging
· 3D GPS-guided injection/biopsy
Support of advanced applications such as strain, elastography, continuous-wave, plane-wave and vector doppler, and photoacoustics
In addition, BioSONIC customers will gain the benefit of Bioscan’s specialized animal handling and image analysis software products, as well as the company’s team of expert applications scientists and service engineers.
“Sonix appreciates the unique demands of sophisticated life sciences researchers,” observed Laurent Pelissier, CEO of Sonix. “Bioscan’s knowledge and experience in the preclinical imaging market will ensure that our differentiated ultrasound technologies are optimized to the needs of these customers.”
The products will be exhibited at the upcoming 2012 World Molecular Imaging Congress in Dublin, Ireland, September 5-8, 2012. Please come to booth #203 to learn more.
Bioscan is a leading supplier of preclinical, nano-tomographic molecular imaging solutions that enable groundbreaking life sciences research. Preclinical imaging uses molecular biomarkers in animals to conduct in vivo studies that generate more relevant, consistent biological data while reducing research cost and complexity. Bioscan’s innovative nuclear (PET & SPECT), 3D optical, ultrasound, X-Ray CT and MRI imaging tools are used by more than 100 leading academic and government research institutions and life sciences companies worldwide to improve their disease, drug discovery and development research. The unique imaging performance enabled by Bioscan‘s patented technologies makes it possible to translate research protocols and results directly from animal models of diseases to human clinical trials, enabling faster, more efficient development of new diagnostics and therapies. Bioscan is a privately held company based in Washington, DC, USA. www.bioscan.com